CompanyGraph
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
2591 · HKEX · China
innogenpharm.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $19.51M, lower than 95% of all stocks globally
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
20.07BHKD2.56B · vs all stocks (USD)
Revenue (TTM)
153.05MCNY19.51M · vs all stocks (USD)
Profit Margin
-259.57%vs Biotechnology peers
52-Week Change
-92.00%vs all stocks
Market Capitalization
20.07BHKD2.56B · vs all stocks (USD)
Enterprise Value
1.34BHKD170.27M · vs all stocks (USD)
Forward P/E
29.35xvs Biotechnology peers
Price to Sales (TTM)
15.60xvs Biotechnology peers
Price to Book (MRQ)
1.67xvs Biotechnology peers
Enterprise to Revenue
8.73xvs Biotechnology peers
Enterprise to EBITDA
-3.38xvs Biotechnology peers
Profit Margin
-259.57%vs Biotechnology peers
Operating Margin
-292.53%vs Biotechnology peers
Return on Assets (TTM)
-17.30%vs Biotechnology peers
Return on Equity (TTM)
-36.91%vs Biotechnology peers
Revenue (TTM)
153.05MCNY19.51M · vs all stocks (USD)
Revenue per Share (TTM)
0.3030CNYUpdated Aug 19, 2026Gross Profit (TTM)
136.23MCNY17.37M · vs all stocks (USD)
EBITDA (TTM)
-395.35MCNY-50.40M · vs all stocks (USD)
Net Income (TTM)
-397.27MCNY-50.65M · vs all stocks (USD)
Operating Cash Flow (TTM)
-343.94MCNY-43.85M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-260.85MCNY-33.26M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
131.51MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
14.45MCNYFY2025 · Dec 31, 2025Gross Profit
117.06MCNYFY2025 · Dec 31, 2025Operating Income
-342.77MCNY-50.83M · vs all stocks (USD)
Pre-tax Income
-341.36MCNYFY2025 · Dec 31, 2025Income Tax Expense
0.00CNYFY2025 · Dec 31, 2025Net Income
-341.36MCNYFY2025 · Dec 31, 2025EBIT
-339.65MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-335.65MCNYFY2025 · Dec 31, 2025Research & Development
205.78MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
180.40MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
7.47MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.72MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
-341.36MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-424.82MCNYFY2025 · Dec 31, 2025Free Cash Flow
-444.79MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
969.09MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-341.36MCNYFY2025 · Dec 31, 2025Stock-based Compensation
14.96MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-5.75MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-5.56MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-87.11MCNYFY2025 · Dec 31, 2025Capital Expenditures
-19.97MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-2.06MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.75BCNYFY2025 · Dec 31, 2025Sale of Investments
3.79BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
24.69MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
172.76MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-32.40MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
762.14MCNYFY2025 · Dec 31, 2025Shares Outstanding
420.29MSharesUpdated Aug 19, 2026Float Shares
253.86MSharesUpdated Aug 19, 2026% Held by Insiders
41.13%vs all stocks
% Held by Institutions
21.48%vs all stocks
Total Cash (MRQ)
1.40BCNY178.71M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.64CNYUpdated Aug 19, 2026Total Debt (MRQ)
193.49MCNY24.67M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1578xvs Biotechnology peers
Current Ratio (MRQ)
2.93xvs Biotechnology peers
Book Value per Share (MRQ)
2.68CNYUpdated Aug 19, 2026Total Assets
1.57BCNY232.98M · vs all stocks (USD)
Total Current Assets
1.48BCNYFY2025 · Dec 31, 2025Total Liabilities
517.61MCNYFY2025 · Dec 31, 2025Total Non-current Assets
92.03MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
13.03MCNYFY2025 · Dec 31, 2025Total Current Liabilities
504.58MCNYFY2025 · Dec 31, 2025Cash
969.32MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
969.32MCNYFY2025 · Dec 31, 2025Other Short-term Investments
235.43MCNYFY2025 · Dec 31, 2025Accounts Receivable
5.56MCNYFY2025 · Dec 31, 2025Inventory
115.94MCNYFY2025 · Dec 31, 2025Accounts Payable
225.08MCNYFY2025 · Dec 31, 2025Short-term Debt
153.30MCNYFY2025 · Dec 31, 2025Long-term Debt
12.96MCNYFY2025 · Dec 31, 2025Common Stock (Book)
456.82MCNYFY2025 · Dec 31, 2025Retained Earnings
-1.84BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.05BCNY156.22M · vs all stocks (USD)
52-Week Low
4.22HKDUpdated Aug 19, 202652-Week High
53.20HKDUpdated Aug 19, 202652-Week Change
-92.00%vs all stocks
50-Day MA
7.77HKDUpdated Aug 19, 2026200-Day MA
21.19HKDUpdated Aug 19, 2026Avg 10-Day Volume
7.08MSharesUpdated Aug 19, 2026Avg 30-Day Volume
3.88MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.9200CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $19.51M, lower than 95% of all stocks globallySignificant
Revenue (USD): 19,512,031.385Global P5: 30,274,777.221
Market cap is $2.56B, above the global median of $1.15BNotable
Market cap (USD): 2,559,061,159.05Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
TransMedics Group Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
GN Store Nord A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Buchang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Immunome Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Sellas Life Sciences Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tarsus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
China Resources Double Crane Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
ApicHope Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Curaleaf Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Regencell Bioscience Holdings Ltd.
Tier 1ProductionApproval-Gated PipelineRule